Macrophage Biomarkers CD68 and CD163 Correlate with CRC Patient Survival (Poster No. 2530 at #AACR2022)

Key Takeaways
  • CRC patient survival correlates with the presence or absence of macrophage biomarkers CD68, CD163, and a lack of PD-L1.
  • Lower levels of ‘M1/anti-tumor’ CD68+ or CD68+CD163– cells correlate with increased survival. Higher levels of ‘M2/pro-tumor’ CD163+ cells showed minimal correlation to survival.
  • Based on these observations, additional biomarkers are needed to better characterize macrophage phenotypes and understand their role in the tumor microenvironment.

Sign up to receive industry and company news, including The Cut Point, Flagship’s quarterly e-newsletter.

Recent Posts